Associate Professor in Pharmaceutical Sciences
Queen's University Belfast
Belfast, Northern Ireland, United Kingdom
Dr Garry Laverty is an Associate Professor in Pharmaceutical Sciences at the School of Pharmacy Queen’ University Belfast. His research focuses on using peptide nanomaterials, primarily self-assembled hydrogels and nanotubes, for drug delivery and biomaterial applications with >£1.3 million support as Principal Investigator from several sources including the EPSRC (EP/S031561/1), MRC (MC_PC_18060), Wellcome Trust (07618/Z/17/Z), Innovate UK (32-08/520268133) and Royal Society (RG150171, IE1609880). He has authored 45 publications relating to peptides and their use within the drug delivery and biomaterial fields. Garry's works (2021) were selected by the EPSRC as a Developing New Therapies Case Study and published within the 2021 Emerging Investigators issue of Soft Matter.
Garry's most recent work relates to the development of an injectable in situ forming peptide hydrogel implant for sustained drug delivery. EPSRC, MRC and Wellcome Trust support has allowed this to be developed primarily for use in HIV/AIDs and combined contraception but this system is also showing promise for use in conditions with medication adherence and drug delivery issues (e.g. Alzheimer's, tuberculosis, depression, schizophrenia, substance abuse, malaria, cancer, ocular delivery, spinal/CNS delivery, vaccines and infection).
Disclosure information not submitted.
Monday, October 17, 2022
3:00 PM – 3:15 PM ET